<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Immunoglobulin light-chain <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> needs to be considered in any patient presenting with <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> with preserved systolic function, heavy <z:mp ids='MP_0002871'>albuminuria</z:mp>, an unexplained <z:hpo ids='HP_0007141'>sensorimotor peripheral neuropathy</z:hpo>, <z:hpo ids='HP_0002240'>hepatomegaly</z:hpo>, or atypical <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MGUS</z:e> (<z:e sem="disease" ids="C0278494" disease_type="Neoplastic Process" abbrv="MGUS">monoclonal gammopathy of undetermined significance</z:e>) or <z:mp ids='MP_0009440'>myeloma</z:mp>.The prognosis of the disease is determined by the levels of cardiac biomarkers and the pretreatment levels of immunoglobulin free light chains </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients with systemic light-chain amyloid require therapy </plain></SENT>
<SENT sid="2" pm="."><plain>There is no presymptomatic phase that warrants observation </plain></SENT>
<SENT sid="3" pm="."><plain>Stem-cell transplantation produces a high response rate but is a viable option in only 20% of patients </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="50858">Corticosteroids</z:chebi>, <z:chebi fb="0" ids="22333">alkylating agents</z:chebi>, immunomodulatory drugs, and <z:chebi fb="0" ids="52726">proteasome inhibitors</z:chebi> <z:hpo ids='HP_0000001'>all</z:hpo> have shown activity in this disorder, and combinations are currently being explored in clinical trials </plain></SENT>
<SENT sid="5" pm="."><plain>Despite advances in the past decade, 30% of patients still die within a year of diagnosis, suggesting that failure to recognize this disorder prior to advanced organ dysfunction remains a major impediment to improving outcomes </plain></SENT>
</text></document>